Patents by Inventor Christoph Ganss

Christoph Ganss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES SPECIFIC TO ABCB5 AND USES THEREOF
    Publication number: 20230203153
    Abstract: Disclosed herein are anti-ABCB5 antibodies possessing superior binding and biological activities, for instance, relative to commercially available ABCB5 antibodies, pharmaceutical compositions comprising such. Also provided herein are therapeutic and diagnostic applications of such anti-ABCB5 antibodies.
    Type: Application
    Filed: April 30, 2021
    Publication date: June 29, 2023
    Applicants: Children's Medical Center Corporation, TICEBA GmbH, RHEACELL GmbH & Co., KG
    Inventors: Markus H. Frank, Christoph Ganss, Christoph Maßlo, Mark Andreas Kluth, Jan Reckenbeil
  • USE OF STEM CELLS FOR TREATMENT OF EXCESSIVE INFLAMMATION
    Publication number: 20230148432
    Abstract: Methods and compositions comprising ABCB5+ stem cell to treat hyper-inflammatory disorders, such as acute respiratory distress syndrome (ARDS) are provided. Such compositions may be used to treat, for example, patients with severe COVID19.
    Type: Application
    Filed: March 30, 2021
    Publication date: May 11, 2023
    Applicants: Children's Medical Center Corporation, TICEBA GmbH
    Inventors: Mark Andreas Kluth, Markus H. Frank, Christoph Ganss
  • ABCB5+ STEM CELL THERAPEUTICS FOR LIVER DISEASE
    Publication number: 20220241339
    Abstract: The invention relates to methods for treating liver disease. For instance a method for treating liver fibrosis in a subject in a subject in need thereof, comprising injecting an isolated population of ABCB5+ stem cells into the subject in an effective amount to treat liver fibrosis in the subject is provided. Methods for inducing liver tissue generation in a subject in need thereof by injecting an isolated population of ABCB5+ stem cells into the subject in an effective amount to generate liver tissue are also provided.
    Type: Application
    Filed: April 24, 2020
    Publication date: August 4, 2022
    Inventors: Markus H. Frank, Christoph Ganss, Mark Andreas Kiuth
  • HIGHLY FUNCTIONAL MANUFACTURED ABCB5+ MESENCHYMAL STEM CELLS
    Publication number: 20220184136
    Abstract: Populations of synthetic ABCB5+ stem cells, wherein greater than 96.8% of the population is an in vitro progeny of physiologically occurring skin-derived ABCB5? positive mesenchymal stem cells are provided. Also provided are methods of making the synthetic cells and methods of use thereof.
    Type: Application
    Filed: March 27, 2020
    Publication date: June 16, 2022
    Applicants: Children's Medical Center Corporation, TICEBA GmbH
    Inventors: Markus H. Frank, Mark Andreas Kluth, Christoph Ganss
  • HIGHLY FUNCTIONAL MANUFACTURED STEM CELLS
    Publication number: 20210095254
    Abstract: Populations of synthetic ABCB5+ stem cells, wherein greater than 96.8% of the population is an in vitro progeny of physiologically occurring skin-derived ABCB5-positive mesenchymal stem cells are provided. Also provided are methods of making the synthetic cells and methods of use thereof.
    Type: Application
    Filed: March 30, 2020
    Publication date: April 1, 2021
    Applicants: Children's Medical Center Corporation, TICEBA GmbH
    Inventors: Markus H. Frank, Andreas Kluth, Christoph Ganss